DOCSLIB.ORG

How COVID-19 Provides Lessons From

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
How COVID-19 Provides Lessons From This Teachable Moment: How COVID-19 Provides Lessons from FDA’s Past and Present That Will Benefit Its Future Preparedness Food and Drug Law Journal 2020 Symposium November 12–13 | Virtual Event This Teachable Moment: How COVID-19 Provides Lessons from FDA’s Past and Present That Will Benefit Its Future Preparedness Food and Drug Law Journal 2020 Symposium November 12–13 | Virtual Event TABLE OF CONTENTS AGENDA SPEAKER BIOGRAPHIES ATTENDEE LIST Food and Drug Law Journal 2020 Symposium This Teachable Moment: How COVID-19 Provides Lessons from FDA’s Past and Present That Will Benefit Its Future Preparedness November 12–13, 2020 Virtual Event Agenda THURSDAY, NOVEMBER 12, 2020 12:00–12:15 PM Welcome Announcements Amy Comstock Rick, President & CEO, FDLI Paige Samson, Director, Innovative Programs and Publications, FDLI 12:15–12:45 PM Keynote Address Dr. Anand Shah, Deputy Commissioner for Medical and Scientific Affairs, Office of the Commissioner, FDA Lowell Zeta, Senior Counselor to the Commissioner, Office of the Commissioner, FDA 12:45–12:50 PM Break 12:50–2:20 PM Paper Presentations Topic: “History, Legislative Innovation, and Future Pandemics” Daniel A. Kracov, Arnold & Porter and Vice Chair, FDLI Board of Directors Topic: “Agencies Unbound: How COVID-19 Prompted Regulatory Flexibility and How to Build on it for the Future” Brian D. Eyink, Elizabeth B. Fawell, Steven B. Steinborn, and Anneke Baran Altieri, Hogan Lovells US LLP Moderator: Laurie Beyranevand, Vermont Law School Discussant: Kalah Auchincloss, Greenleaf Health, Inc. 2:20–2:30 PM Break 2:30–3:15 PM Paper Presentation Topic: “The American Pharmaceutical Supply Chain: Will COVID-19 Drive Manufacturing Back Home?” Gregory H. Levine, Jenna McCarthy*, and Beth P. Weinman, Ropes & Gray LLP and Grant Sims*, NYU Stern School of Business Moderator: Marian J. Lee, Gibson, Dunn & Crutcher LLP © 2020 by the Food and Drug Law Institute (FDLI) *Author is not presenting at the FDLJ 2020 Symposium 1 Food and Drug Law Journal 2020 Symposium This Teachable Moment: How COVID-19 Provides Lessons from FDA’s Past and Present That Will Benefit Its Future Preparedness November 12–13, 2020 Virtual Event Agenda Discussant: Ralph F. Hall, University of Minnesota Law School and Leavitt Partners, LLC 3:15–3:30 PM Break 3:30–5:00 PM Paper Presentations Topic: “Vaccine-Related Liability: Past Approaches, Current Challenges, and Proposals for Encouraging Future Innovation and More Widespread Vaccine Use” Camille L. Fletcher, Greg Margolis*, and John D. Winter, Patterson, Belknap, Webb & Tyler LLP Topic: “A Test of the Emergency (Use Authorization) System: Challenges in FDA Regulation of COVID-19 Diagnostics” Jeffrey N. Gibbs, and Gail H. Javitt*, Hyman, Phelps & McNamara, P.C. Moderator: James T. O’Reilly, University of Cincinnati, and Chair, Food and Drug Law Journal Editorial Advisory Board Discussant: J.R. McNair, Winston & Strawn LLP 5:00–5:30 PM Networking Event FRIDAY, NOVEMBER 13, 2020 12:00 PM Welcome Remarks Sonia L. Canzater, Senior Associate, Hepatitis Policy Project, O’Neill Institute for National and Global Health Law, Georgetown University Law Center Paige Samson, Director, Innovative Programs and Publications, FDLI 12:00–1:30 PM Paper Presentations Topic: “How We Got Here: FDA Emergency Use Authorization from 9/11 to COVID-19” Jonathan Iwry, Harvard Law School © 2020 by the Food and Drug Law Institute (FDLI) *Author is not presenting at the FDLJ 2020 Symposium 2 Food and Drug Law Journal 2020 Symposium This Teachable Moment: How COVID-19 Provides Lessons from FDA’s Past and Present That Will Benefit Its Future Preparedness November 12–13, 2020 Virtual Event Agenda Topic: “Assessing COVID-19 Emergency Use Authorizations” Efthimios Parasidis, Patricia J. Zettler*, and Micah Berman*, The Ohio State University Moderator: Joseph Page, Georgetown University Discussant: Nathan A. Brown, Akin Gump Strauss Hauer & Feld LLP 1:30–1:45 PM Break 1:45–2:30 PM Paper Presentation Topic: “One Health Pandemic Prevention and Mitigation: The Role of FDA” Margaret Foster Riley, University of Virginia, and Member, FDLI Board of Directors Discussants: Bernadette Dunham, Milken Institute School of Public Health, George Washington University and Advisor to the FDA One Health Initiative, Center for Veterinary Medicine, FDA Capt. Brianna Skinner, Office of the Commissioner, Office of Counterterrorism and Emerging Threats, FDA 2:30–2:45 PM Break 2:45–4:15 PM Paper Presentations Topic: “Federal Law’s Protective Quilt: Understanding the Statutory Regimes for Personal Protective Equipment (PPE) and Recommending an Additional Piece” John F. Johnson III, Shook, Hardy & Bacon LLP Topic: “Regulatory Reactivity: FDA and the Response to COVID-19” Yaniv Heled, Georgia State College of Law Ana Santos Rutschman, St. Louis University School of Law Liza Vertinsky, Emory University School of Law Discussants: Lewis Grossman, American University Alan G. Minsk, Arnall Golden Gregory LLP Carolina M. Wirth, Arnall Golden Gregory LLP © 2020 by the Food and Drug Law Institute (FDLI) *Author is not presenting at the FDLJ 2020 Symposium 3 Food and Drug Law Journal 2020 Symposium November 12-13, 2020 ANNEKE BARAN ALTIERI is an associate at Hogan Lovells US LLP where she provides practical legal and policy solutions to clients at all levels of the food supply chain. She is committed to helping clients navigate the complex state and federal regulatory landscape, without sacrificing business innovation. Anneke advises clients on US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) labeling and advertising requirements, food safety issues, and enforcement actions. Anneke also has experience counseling clients in the consumer product, pharmaceutical, and health care industries and maintains an active pro bono practice. Drawing on previous regulatory experience with the Department of Homeland Security, Anneke understands the nuanced intersection of government and industry. Before arriving at Hogan Lovells, Anneke graduated from the University of Virginia School of Law, where she was a Fellow for the Legal Research and Writing Program and served on the editorial board of the Virginia Law and Business Review. KALAH AUCHINCLOSS is Senior Vice President, Regulatory Compliance and Deputy General Counsel at Greenleaf Health, LLC. She has more than a decade of food and drug legal, policy, and regulatory experience at FDA, on Capitol Hill, and in the private sector. Ms. Auchincloss spent six years at FDA, most recently as Deputy Chief of Staff for two FDA Commissioners: Dr. Robert Califf and Dr. Scott Gottlieb. As Deputy Chief of Staff, she worked with senior FDA leadership to manage crises, develop policy decisions, implement communications strategies, and liaise with the Department of Health and Human Services, the White House, and other agencies. Ms. Auchincloss was also a primary point of contact in the immediate Office of the Commissioner for the six FDA Centers and other components of the Commissioner’s Office. She has also served in FDA’s Center for Drug Evaluation and Research (CDER) as a regulatory counsel in the Office of Regulatory Policy, and as Director of CDER’s Office of Unapproved Drugs and Labeling Compliance in the Office of Compliance, leading a team of more than 50 staff working on pharmacy compounding, unapproved drugs, over-the- counter drugs, and other enforcement issues. Before joining FDA, Ms. Auchincloss was an associate at the law firm Foley Hoag LLP, in the firm’s health care practice group. She holds a BA with honors from Williams College, a JD with honors from Georgetown University Law Center, and an MPH from Harvard University. MICAH BERMAN is an associate professor of public health and law at The Ohio State University’s College of Public Health and Michael E. Moritz College of Law. He teaches courses on public health law, health care law, and tobacco regulation, and he is a co-author of a The New Public Health Law: A Transdisciplinary Approach to Practice and Advocacy (Oxford University Press & APHA Press, 2018). His current research, funded by the National Cancer Institute, seeks to inform the FDA’s regulation of tobacco products. Before joining Ohio State’s faculty in 2013, Professor Berman directed policy centers that provided legal and policy support to state and local health departments in Ohio, New York, and Vermont. He has also served as a senior advisor to the FDA’s Center for Tobacco Products and as a trial attorney with the US Department of Justice. He received his JD with distinction from Stanford Law School and his BA in Public Policy from Brandeis University. LAURIE BEYRANEVAND is Senior Faculty Fellow of Food Law and Policy at the Center for Agriculture and Food Systems, and a professor of law at Vermont Law School. Prior to joining the faculty at Vermont Law School, Laurie was a Staff Attorney at Vermont Legal Aid where she represented adults and children in individual cases and class action litigation advocating for access to health care, education equality, and civil rights. Laurie has published a number of scholarly articles and book chapters that focused on the connections between human health and food systems. Her work has been cited in petitions to major federal agencies, books, blogs, and articles, and she has been quoted in Politico, Mother Jones, the Christian Science Monitor, Climate Wire, the Washington Post, and E & E Greenwire, among others. She is an appointed member of the Food and Drug Law Institute and Georgetown Law School’s Food and Drug Law Journal Editorial Advisory Board, a founding member of the Academy of Food Law and Policy, and the Chair of the Agriculture and Food Law Section of the American Association of Law Schools. NATHAN A. BROWN is a partner in the Health Care and Life Sciences practice at Akin Gump. He has worked extensively in the FDA regulatory and compliance field and is sought after for his understanding and insights into the regulation and marketing of innovative medical technologies.
Load more

Recommended publications
  • “I Have SMA, SMA Doesn't Have Me”- a Qualitative Snapshot Into The
    “I have SMA, SMA doesn’t have me”- A Qualitative Snapshot into the Challenges, Successes, and Quality of Life of Adolescents and Young Adults with SMA Allison Joy Mazzella ( [email protected] ) Cure SMA https://orcid.org/0000-0002-0346-8659 Mary Curry Cure SMA Lisa Belter Cure SMA Rosangel Cruz Cure SMA Jill Jarecki Cure SMA Research Keywords: Spinal Muscular Atrophy, Quality of Life in SMA Adolescents and Young Adults, Qualitative Research, Emotional Health, Disability, Peer-Support Group, Accessibility, Fatigue, Dependence. Posted Date: October 19th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-49014/v2 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Version of Record: A version of this preprint was published on February 22nd, 2021. See the published version at https://doi.org/10.1186/s13023-021-01701-y. Page 1/29 Abstract Background: With the approval of three treatments for spinal muscular atrophy (SMA) and several promising therapies on the horizon, the SMA adolescent and young adult populations are expected to evolve in the coming years. It is imperative to understand this cohort as it exists today to provide optimal care and resources, as well as to assess possible treatment effects over time. In 2018, Cure SMA launched two initiatives geared towards understanding adolescents and young adults with SMA, ages 12- 25. First, Cure SMA launched a Quality of Life (QoL) survey to capture quantitative and qualitative information on this specic age demographic. Concurrently, Cure SMA invited SMA-affected individuals, ages 12-25, to create a three-minute video on their everyday experiences living with SMA.
    [Show full text]
  • Law School Record, Vol. 11, No. 1 (Winter 1963) Law School Record Editors
    University of Chicago Law School Chicago Unbound The nivU ersity of Chicago Law School Record Law School Publications Winter 1-1-1963 Law School Record, vol. 11, no. 1 (Winter 1963) Law School Record Editors Follow this and additional works at: http://chicagounbound.uchicago.edu/lawschoolrecord Recommended Citation Law School Record Editors, "Law School Record, vol. 11, no. 1 (Winter 1963)" (1963). The University of Chicago Law School Record. Book 29. http://chicagounbound.uchicago.edu/lawschoolrecord/29 This Book is brought to you for free and open access by the Law School Publications at Chicago Unbound. It has been accepted for inclusion in The University of Chicago Law School Record by an authorized administrator of Chicago Unbound. For more information, please contact [email protected]. THE UNIVERSITY OF CHICAGO 11 Volume WINTER 1963 Number 1 Seven New Appointments The Class of 1965 Four new members, including one from Ghana, have The class entering the School in October, besides being been to the of the Law School. appointed Faculty of excellent quality, shows great diversity of origins, both Three distinguished lawyers from abroad also have as to home states and undergraduate degrees. The 149 been members of the appointed visiting Law School students in the class come to the School from thirty-six faculty during 1963. states, plus the District of Columbia and Puerto Rico; they hold degrees from eighty-four different universities Continued on page 12 At the dinner for entering students, Visiting Committee and Alumni Board, left to right: Kenneth Montgomery, Charles R. Kaufman, Edmund Kitch, Class of 1964, Paul Kitch, JD'35, and Charles Boand, JD'33.
    [Show full text]
  • The Honorable Eliot Spitzer State Capitol Albany, NY 12224 Antonia
    The Honorable Eliot Spitzer State Capitol Albany, NY 12224 Antonia C. Novello, M.D., M.P.H., Dr. P.H. New York State Commissioner of Health New York State Department of Health Corning Tower Empire State Plaza Albany, NY 12237 Dear Governor-elect Spitzer and Commissioner Novello: We write on behalf of the memberships of four committees of the New York City Bar Association -- Corrections, Health Law, Mental Health Law, and Social Welfare Law -- to urge New York State to cease its current practice of terminating Medicaid eligibility for individuals incarcerated in state and local correctional facilities. We urge the State instead to suspend Medicaid eligibility. Suspension will allow incarcerated Medicaid beneficiaries to receive needed benefits promptly upon release, thereby promoting continuity of care. Under the present system, formerly eligible individuals must reapply for Medicaid upon their release from correctional facilities. This process typically results in a significant delay in these individuals’ ability to access needed care in their communities. Members of this population already are at high risk for physical and mental illnesses, including substance addiction. Additionally, many releasees have serious chronic conditions for which they received care while in prison. It is imperative that they receive swift access to adequate and affordable medical care upon release. Failure to receive such assistance can hinder their ability to become productive members of the community, and in fact, may threaten the safety and well-being of the communities to which formerly incarcerated individuals return. Moreover, while awaiting the reinstatement of Medicaid coverage, formerly incarcerated individuals frequently turn to emergency rooms and other costly forms of care for assistance.
    [Show full text]
  • Full Prescribing Information for Systemic Corticosteroids (Equivalent to Oral Prednisolone at 1 Mg/Kg/Day) ZOLGENSMA
    HIGHLIGHTS OF PRESCRIBING INFORMATION For patients with unremarkable findings, taper the corticosteroid dose These highlights do not include all the information needed to use over the next 28 days. If liver function abnormalities persist, continue ZOLGENSMA safely and effectively. See full prescribing information for systemic corticosteroids (equivalent to oral prednisolone at 1 mg/kg/day) ZOLGENSMA. until findings become unremarkable, and then taper the corticosteroid dose over the next 28 days. Consult expert(s) if patients do not respond ® ZOLGENSMA (onasemnogene abeparvovec-xioi) suspension, for adequately to the equivalent of 1 mg/kg/day oral prednisolone. (2.1) intravenous infusion Initial U.S. Approval: 2019 ---------------------DOSAGE FORMS AND STRENGTHS---------------------- ZOLGENSMA is a suspension for intravenous infusion, supplied as WARNING: ACUTE SERIOUS LIVER INJURY single-use vials. (3) See full prescribing information for complete boxed warning. ZOLGENSMA is provided in a kit containing 2 to 9 vials, as a combination of Acute serious liver injury and elevated aminotransferases can occur 2 vial fill volumes (either 5.5 mL or 8.3 mL). All vials have a nominal with ZOLGENSMA. (5.1) concentration of 2.0 × 1013 vector genomes (vg) per mL. Each vial of Patients with pre-existing liver impairment may be at higher risk. ZOLGENSMA contains an extractable volume of not less than either 5.5 mL (8.6) or 8.3 mL. (3) Prior to infusion, assess liver function of all patients by clinical -------------------------------CONTRAINDICATIONS------------------------------ examination and laboratory testing (e.g., hepatic aminotransferases None. (4) [aspartate aminotransferase (AST) and alanine aminotransferase (ALT)], total bilirubin, and prothrombin time). Administer systemic ------------------------WARNINGS AND PRECAUTIONS----------------------- corticosteroid to all patients before and after ZOLGENSMA infusion.
    [Show full text]
  • Former Enron Vice President Sherron Watkins on the Enron Collapse
    UC Irvine UC Irvine Previously Published Works Title Former Enron vice president Sherron Watkins on the Enron collapse Permalink https://escholarship.org/uc/item/9pb4r7nj Journal Academy of Management Executive, 17(4) ISSN 1079-5545 Author Pearce, JL Publication Date 2003 DOI 10.5465/ame.2003.11851888 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California ? Academy of Management Executive, 2003, Vol. 17, No. 4 Former Enron vice president Sherron Watkins on the Enron collapse Academy Address, August 3, 2003, by Sherron Watkins Introduction to the address by Academy President Jone L. Pearce It is my pleasure to introduce Sherron Watkins, the Academy of Management's 2003 Distinguished Executive Speaker. By now, her story as the former vice president of Enron Corporation who tried to bring what she called "an elaborate accounting hoax" to the attention of Enron's chief executive officer is well known. In August 2001, responding to his invitation to employees to put any concerns in a comment box, she did so. When he did not address her explosive charges at a subsequent company-wide meeting, she sought a face-to-face meeting with him. A month later the CEO announced to employees that "our financial liquidity has never been stronger," while exercising his own $1.5 billion in stock options, just ahead of the company's announcement of a $618 million quarterly loss. When United States Congressional investigators uncovered her letter buried in boxes of documents, they brought Ms. Watkins before the United States Senate in February 2002 to testify about her warnings.
    [Show full text]
  • Desperately Seeking Solutions: Using Implementation-Based Solutions for the Troubles of Information Privacy in the Age of Data Mining and the Internet Society
    Maine Law Review Volume 56 Number 1 SYMPOSIUM: Topics in Law and Article 3 Technology January 2004 Desperately Seeking Solutions: Using Implementation-Based Solutions for the Troubles of Information Privacy in the Age of Data Mining and the Internet Society Tal Z. Zarsky Follow this and additional works at: https://digitalcommons.mainelaw.maine.edu/mlr Part of the Computer Law Commons, Internet Law Commons, and the Privacy Law Commons Recommended Citation Tal Z. Zarsky, Desperately Seeking Solutions: Using Implementation-Based Solutions for the Troubles of Information Privacy in the Age of Data Mining and the Internet Society, 56 Me. L. Rev. 13 (2004). Available at: https://digitalcommons.mainelaw.maine.edu/mlr/vol56/iss1/3 This Article is brought to you for free and open access by the Journals at University of Maine School of Law Digital Commons. It has been accepted for inclusion in Maine Law Review by an authorized editor of University of Maine School of Law Digital Commons. For more information, please contact [email protected]. DESPERATELY SEEKING SOLUTIONS: USING IMPLEMENTATION-BASED SOLUTIONS FOR THE TROUBLES OF INFORMATION PRIVACY IN THE AGE OF DATA MINING AND THE INTERNET SOCIETY Tal Z. Zarsky INTRODUCTION I. SOLUTIONS AND THE INFORMATION FLOW A. Collection B. Analysis C. Implementation D. Summing Up II. PREFERRING THE REGULATION OF IMPLEMENTATION TO COLLECTION A. Virtual Babies and Virtual Bathwater 1. Subsidiesfor Startups and the Importance of Innovation 2. CreatingValue B. The "Personal-Information-Based"Transaction 1. Myopia and CorrectiveLenses 2. Collectees vs. Subjects of Manipulation III. DOUBLECLICK, IN.-A PRACTICAL PERSPECTIVE A. Collection B. Analysis C.
    [Show full text]
  • Chancellor Kent: an American Genius
    Chicago-Kent Law Review Volume 38 Issue 1 Article 1 April 1961 Chancellor Kent: An American Genius Walter V. Schaefer Follow this and additional works at: https://scholarship.kentlaw.iit.edu/cklawreview Part of the Law Commons Recommended Citation Walter V. Schaefer, Chancellor Kent: An American Genius, 38 Chi.-Kent L. Rev. 1 (1961). Available at: https://scholarship.kentlaw.iit.edu/cklawreview/vol38/iss1/1 This Article is brought to you for free and open access by Scholarly Commons @ IIT Chicago-Kent College of Law. It has been accepted for inclusion in Chicago-Kent Law Review by an authorized editor of Scholarly Commons @ IIT Chicago-Kent College of Law. For more information, please contact [email protected], [email protected]. CHICAGO-KENT LAW REVIEW Copyright 1961, Chicago-Kent College of Law VOLUME 38 APRIL, 1961 NUMBER 1 CHANCELLOR KENT: AN AMERICAN GENIUS Walter V. Schaefer* T HIS IS THE FIRST OPPORTUNITY I have had, during this eventful day, to express my deep appreciation of the honor that you have done me.' I realize, of course, that there is a large element of symbolism in your selection of Dr. Kirkland and me to be the recipients of honorary degress, and that through him you are honoring the bar of our community, and through me the judges who man its courts. Nevertheless, both of us are proud and happy that your choice fell upon us. I am particularly proud to have been associated with Weymouth Kirkland on this occasion. His contributions to his profession are many. One of the most significant was the pioneer role that he played in the development of a new kind of court room advocacy.
    [Show full text]
  • Daniel L. Feldman [email protected] 533.22 Haaren Hall, John Jay College of Criminal Justice, 524 West 59 Street, New York, NY
    Daniel L. Feldman [email protected] 533.22 Haaren Hall, John Jay College of Criminal Justice, 524 West 59 Street, New York, NY Experience Director, MPA-Inspection and Oversight Program 2019- Professor of Public Management 2014-2019 Associate Professor of Public Management 2010-2014 John Jay College of Criminal Justice, 445 W. 59 St., NYC 10019 Courses offered: Administrative Law; Ethics, Integrity, and Accountability in Public Management; Public Sector Inspection and Oversight; Oversight by Independent, Regulatory & Political Authorities; Policy Analysis Special Counsel for Law and Policy 2007-2010 Office of the State Comptroller, 633 Third Avenue, NYC 10017 Advised Comptroller on legal and policy issues; supervised divestment of Iran- and Sudan- related holdings by New York Common Retirement Fund; recommended revision, approval, or overrule of hearing officer decisions on pension appeals; assessed relationship between corporate governance and social accountability policies and investment returns; drafted complete revision of body of New York’s law on unclaimed funds. Executive Director and General Counsel 2005-2007 New York State Trial Lawyers Association, 132 Nassau St., NYC 10038 Operating chief of 4000-member association of attorneys, with responsibility for overseeing research, lobbying, political fundraising, finance, media, and personnel. Reported to annually- elected president and board of directors. Reversed 7-year financial decline, strengthened representation in national body by 33 percent, created first new regional affiliate (“Mid- Hudson”) in seven years, won enactment of two new laws, won crucial modifications sought by membership to new court rules on attorney advertising. Assistant Deputy Attorney General 1999–2005 Office of the Attorney General, 120 Broadway, Rm.
    [Show full text]
  • The Pending Determination of the Legality of Internet Gambling in the United States
    THE PENDING DETERMINATION OF THE LEGALITY OF INTERNET GAMBLING IN THE UNITED STATES Internet gambling has been targeted on many fronts in the United States, including Congress, the courts, the Bush Administration and credit card agencies. This iBrief details recent trends in the regulation of online gaming, and concludes that while absolute prohibitions may be ineffective, the combined resistance of these institutions will prevent the industry from expanding its customer base. An Overview There can be little doubt that Internet gambling means big business around the world. Online gaming sites have won $4.1 billion from bettors this year, and that number is expected to increase to an estimated $6 billion next year.1 Gamblers in the United States are responsible for between 50 percent and 65 percent of that amount.2 This iBrief will discuss four current developments that will determine the course of evolution of the Internet gambling industry: • First, the Internet Gambling Enforcement Bill3 passed last year in the United States House of Representatives.4 This bill sought to prevent online gambling sites from using credit card instruments in their transactions.5 The Senate never voted on the proposed legislation before the 107th Congress adjourned, so any attempt to regulate Internet gambling must begin again with the 108th Congress. Nonetheless, the House vote signaled interest by lawmakers in the issue of Internet gambling regulation. • The second development is the move by credit card companies to prohibit the use of their cards in online gaming transactions.6 This strategic move by the 1 Jeff Simpson, Online Gaming Decision Panned: Official Deems Net Bets Illegal In Letter, LAS VEGAS REV.-J., Sept.
    [Show full text]
  • Filling Vacancies in the Office of Lieutenant Governor
    MAY 2009 CITIZENS UNION | ISSUE BRIEF AND POSITION STATEMENT Filling Vacancies in the Office of Lieutenant Governor INTRODUCTION Citizens Union of the City of Shortly after Citizens Union’s last report on the subject of filling vacancies in February 2008, New York is an independent, former Governor Eliot Spitzer resigned from the office of governor and former Lieutenant non-partisan civic organization of Governor David A. Paterson assumed the role of New York’s fifty-fifth governor. Although the members dedicated to promoting good government and political reform in the voters elected Paterson as lieutenant governor in 2006, purposefully to fill such a vacancy in the city and state of New York. For more office of governor should it occur, his succession created a vacancy in the office of lieutenant than a century, Citizens Union has governor, and, more importantly, created confusion among citizens and elected officials in served as a watchdog for the public Albany about whether the current Temporary President of the Senate who serves as acting interest and an advocate for the Lieutenant Governor can serve in both positions simultaneously. This unexpected vacancy common good. Founded in 1897 to fight the corruption of Tammany Hall, exposed a deficiency in the law because no process exists to fill permanently a vacancy in the Citizens Union currently works to position of lieutenant governor until the next statewide election in 2010. ensure fair elections, clean campaigns, and open, effective government that is Though the processes for filling vacancies ordinarily receive little attention, the recent number accountable to the citizens of New of vacancies in various offices at the state and local level has increased the public’s interest in York.
    [Show full text]
  • NY Baranovich BSG Sports Cards and Memorabilia Ebay Store
    B 199- Sunn nm rimes mace. Sepear Cot . O 1993 Juan Bl .ulavey Yc. -SWmbergs penonl m st.d d sci .12 p . rype.494 PUaajEA .NYC 10013 f LawPeducts $uprtmt elourf of fljt $faft of Nrfu Qork Index No. 0 016 98 Gunk of N ELX)YoP,k Date pure 6/1/0/ Plaintiff(s) designate(S) New York State of New York County as the place of trial. The basis of the venue is CPLR§§503, 509 Plaintiffs) against summons Robert A . Baranovich, Steven R . Baranovich, and Plaintiff(s) reside(s) at BS@G Sports Cards and Memorabilia 120 Broadway EBAY Store New York, NY 10271-0332 Defendant(s) County of New York To the above named Defendant(s) Vim art IjErnJIg1 SUmmnnVb to answer the complaint in this action and to serve a copy of your answer, or, if the complaint is not served with this summons, to serve a notice of appearance, on the Plaintiff's Attorney(s) within 2 0 days after the service of this summons, exclusive of the day of service (or within 30 days after the service is complete if this summons is not personally delivered to you within the State of New York); and in case of your failure to appear or answer, judgment will be taken against you by default for the relief demanded in the complaint. Dated, v' h yO$ , h \, Attorney(s) for Plaintiff 1lfl~ .2'1 ;2ob9 0 an~P ce Address Defendant's address: war e tan State of New York Robert A . Baranovich Office of the Attorney General 65 Amsterdam Avenue 120 Broadway 26th Floor West Babylon, NY 11704 New York, NY 10271-0332 Steven R .
    [Show full text]
  • Health Economic Evaluation of Gene Replacement Therapies
    University of Groningen Health economic evaluation of gene replacement therapies Aballéa, Samuel; Thokagevistk, Katia; Velikanova, Rimma; Simoens, Steven; Annemans, Lieven; Antonanzas, Fernando; Auquier, Pascal; François, Clément; Fricke, Frank-Ulrich; Malone, Daniel Published in: Journal of market access & health policy DOI: 10.1080/20016689.2020.1822666 IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2020 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Aballéa, S., Thokagevistk, K., Velikanova, R., Simoens, S., Annemans, L., Antonanzas, F., Auquier, P., François, C., Fricke, F-U., Malone, D., Millier, A., Persson, U., Petrou, S., Dabbous, O., Postma, M., & Toumi, M. (2020). Health economic evaluation of gene replacement therapies: Methodological issues and recommendations . Journal of market access & health policy, 8(1), [1822666 ]. https://doi.org/10.1080/20016689.2020.1822666 Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
    [Show full text]